Uptake and safety of hepatitis A vaccination during pregnancy: A Vaccine Safety Datalink study

Groom, Holly; Smith, Ning; Irving, Stephanie A.; Koppolu, Padma; Benitez, Gabriela Vazquez; Kharbanda, Elyse O.; Daley, Matthew F.; Donahue, James G.; Getahun, Darios; Jackson, Lisa A.; Klein, Nicola P.; McCarthy, Natalie L.; Nordin, James D.; Panagiotakopoulos, Lakshmi; Naleway, Allison L.

doi:10.1016/j.vaccine.2019.09.043

Cited by 28 publications

(11 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A multisite study ( 278 ) in CDC’s Vaccine Safety Datalink (VSD), a population-based research and surveillance data system ( 20 ), of maternal HepA vaccination found that HepA vaccine administration during pregnancy was not associated with increased risk for a range of adverse events examined among pregnancies resulting in live births. However, an association was found between maternal HepA vaccination and infants who were small for gestational age.…”

Section: Prophylaxis Against Hav Infectionmentioning

confidence: 99%

Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020

Nelson¹,

Weng²,

Hofmeister³

et al. 2020

MMWR Recomm. Rep.

157

146

View full text Add to dashboard Cite

Summary Hepatitis A is a vaccine-preventable, communicable disease of the liver caused by the hepatitis A virus (HAV). The infection is transmitted via the fecal-oral route, usually from direct person-to-person contact or consumption of contaminated food or water. Hepatitis A is an acute, self-limited disease that does not result in chronic infection. HAV antibodies (immunoglobulin G [IgG] anti-HAV) produced in response to HAV infection persist for life and protect against reinfection; IgG anti-HAV produced after vaccination confer long-term immunity. This report supplants and summarizes previously published recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding the prevention of HAV infection in the United States. ACIP recommends routine vaccination of children aged 12–23 months and catch-up vaccination for children and adolescents aged 2–18 years who have not previously received hepatitis A (HepA) vaccine at any age. ACIP recommends HepA vaccination for adults at risk for HAV infection or severe disease from HAV infection and for adults requesting protection against HAV without acknowledgment of a risk factor. These recommendations also provide guidance for vaccination before travel, for postexposure prophylaxis, in settings providing services to adults, and during outbreaks

show abstract

Section: Prophylaxis Against Hav Infectionmentioning

confidence: 99%

Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020

Nelson¹,

Weng²,

Hofmeister³

et al. 2020

MMWR Recomm. Rep.

157

146

View full text Add to dashboard Cite

show abstract

“…The vaccine does not seem to be associated with any adverse outcomes, except for small for gestational age neonates. However, this might be because women who were vaccinated had underlying diseases or conditions which may have led to this adverse outcome 23 Hepatitis B vaccine: …”

Section: Optional Vaccinesmentioning

confidence: 99%

“…However, this might be because women who were vaccinated had underlying diseases or conditions which may have led to this adverse outcome. 23 Hepatitis B vaccine:…”

Section: Op Tional Vaccine Smentioning

confidence: 99%

FIGO Statement: Vaccination in pregnancy

Nicholson

Kim

Nassar

et al. 2020

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Pregnant women and their fetuses are among the vulnerable populations that can be severely affected by communicable diseases. As such, some vaccines such as the influenza and the Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) vaccines are strongly recommended in each pregnancy, with generally safe profiles. Other vaccines can be offered based on risk factors, and only when the benefits of receiving them outweigh the risks. Development of vaccines against group B streptococcus infection and respiratory syncytial virus infection are of great importance. In this paper, the recommendations for administration of each vaccine during pregnancy are discussed. The FIGO Committee for Safe Motherhood and Newborn Health Committee endorses the recommendations to vaccinate all pregnant women against influenza during the influenza season at any time during the pregnancy and against Tdap preferably between the 27th and 36th weeks of pregnancy in each pregnancy.

show abstract

“…(115) For women negative for HBV markers, vaccination should be considered and is safe in pregnancy. (116) Regarding antiviral safety, lamivudine, telbivudine, and tenofovir disoproxil fumarate (TDF) have been extensively studied, with no associated teratogenicity, even in the first trimester, (117) and no increased risk of congenital malformations, prematurity, or low Apgar scores. (118) (Table 4)…”

Section: Hepatitis Bmentioning

confidence: 99%

Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases

et al. 2021

View full text Add to dashboard Cite

Uptake and safety of hepatitis A vaccination during pregnancy: A Vaccine Safety Datalink study

Cited by 28 publications

References 29 publications

Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020

Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020

FIGO Statement: Vaccination in pregnancy

Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases

Contact Info

Product

Resources

About